Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Public ClinicalTrials.gov record NCT06731478. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)
Study identification
- NCT ID
- NCT06731478
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Daiichi Sankyo
- Industry
- Enrollment
- 726 participants
Conditions and interventions
Conditions
Interventions
- Chemotherapy Drug
- Trastuzumab Drug
- Trastuzumab Deruxtecan Drug
- pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 26, 2025
- Primary completion
- May 31, 2028
- Completion
- Jan 31, 2030
- Last update posted
- Mar 15, 2026
2025 – 2030
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale Cancer Center | New Haven | Connecticut | 06511 | Not yet recruiting |
| Orchard Healthcare Research Inc. | Skokie | Illinois | 60077 | Recruiting |
| University of Kansas Medical Center Research Institute, Inc. | Kansas City | Kansas | 66160 | Not yet recruiting |
| Maryland Oncology Hematology, P.A. | Silver Spring | Maryland | 20904 | Not yet recruiting |
| Tufts Medical Center | Boston | Massachusetts | 02111 | Recruiting |
| University of Michigan Comprehensive Cancer Center Michigan Medicine | Ann Arbor | Michigan | 48109 | Not yet recruiting |
| Minnesota Oncology Hematology, P.A. | Minneapolis | Minnesota | 55404 | Withdrawn |
| Memorial Sloan Kettering Cancer Center - MAIN | New York | New York | 10065 | Recruiting |
| Montefiore Medical Center | The Bronx | New York | 10467 | Recruiting |
| Providence Portland Medical Center | Portland | Oregon | 97213 | Recruiting |
| Penn State University Milton S. Hershey Medical Center | Hershey | Pennsylvania | 17033 | Not yet recruiting |
| Prisma Health Cancer Institute, ITOR, CRU | Greenville | South Carolina | 29605 | Not yet recruiting |
| Tennessee Oncology Nashville Midtown | Nashville | Tennessee | 37203 | Withdrawn |
| UT Southwestern Medical Center | Dallas | Texas | 75235 | Not yet recruiting |
| Texas Oncology, P.A. - Tyler | Tyler | Texas | 75702 | Not yet recruiting |
| Virginia Oncology Associates | Norfolk | Virginia | 23502-1871 | Not yet recruiting |
| Blue Ridge Cancer Care | Roanoke | Virginia | 24014 | Not yet recruiting |
| Wenatchee Valley Hospital & Clinics | Wenatchee | Washington | 98801 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 231 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06731478, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 15, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06731478 live on ClinicalTrials.gov.